Methylpropyltryptamine
Methylpropyltryptamine, also known as N-methyl-N-propyltryptamine, is a psychedelic drug of the tryptamine family. It is a homologue of methylethyltryptamine.
In his book TiHKAL, Alexander Shulgin described MPT's effects as being unknown and its dose as being greater than 50mg orally.
Chemistry
Detection
An analytical method for MPT's detection has been reported.
In 2019, Chadeayne et al. published the crystal structure of MPT. The authors describe the structure as "...a single molecule in the asymmetric unit, with an indole group that demonstrates a mean deviation from planarity of 0.015 A°."
Analogues
Analogues of MPT include 4-HO-MPT, 5-MeO-MPT, methylethyltryptamine, ethylpropyltryptamine, ethylisopropyltryptamine, and dipropyltryptamine, among others.
Canada
MPT is not a controlled substance in Canada as of 2025.
MPT is not an explicitly controlled substance in the United States. However, it is an isomer of diethyltryptamine, which is a schedule I controlled substance in this country, and so may be considered a controlled substance in the United States similarly.